Kymab Announces Abstracts to be Presented at the 24th EHA Annual Congress

Cambridge, UK; May 16 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced that two abstracts describing KY1049, Kymab’s fully-human Factor VIII (FVIII)-mimetic bispecific antibody, will be presented at the 24th European Hematology Association’s Annual Congress 2019 in Amsterdam, Netherlands, June 13-16. An abstract containing a pre-clinical evaluation of Kymab’s proprietary FVIII-mimetic antibody will be presented as an oral presentation. A poster presentation introduces Kymab’s proprietary IntelliSelect® Bispecifics platform which can generate diverse and extensive panels of fully human, common light chain bispecific antibodies. Developed using high-throughput haemostatic assays, KY1049 is the first CLC bispecific molecule produced using the IntelliSelect® Bispecifics platform.